Dietary capsaicin prevents nonalcoholic fatty liver disease through transient receptor potential vanilloid 1-mediated peroxisome proliferator-activated receptor δ activation

被引:75
|
作者
Li, Qiang [1 ]
Li, Li [1 ]
Wang, Fei [1 ]
Chen, Jian [1 ]
Zhao, Yu [1 ]
Wang, Peijian [1 ]
Nilius, Bernd [2 ]
Liu, Daoyan [1 ]
Zhu, Zhiming [1 ]
机构
[1] Third Mil Med Univ, Chongqing Inst Hypertens, Dept Hypertens & Endocrinol, Ctr Hypertens & Metab Dis,Daping Hosp, Chongqing 400042, Peoples R China
[2] Katholieke Univ Leuven, Lab Ion Channel Res, Dept Cell Mol Med, B-3000 Louvain, Belgium
来源
基金
中国国家自然科学基金;
关键词
Autophagy; Lipolysis; NAFLD; PPAR delta; TRPV1; MULTIDISCIPLINARY APPROACH; CATION CHANNELS; AUTOPHAGY; OBESITY; STEATOHEPATITIS; METABOLISM; LIPOGENESIS; EXPRESSION; DEFICIENT; PATHWAYS;
D O I
10.1007/s00424-013-1274-4
中图分类号
Q4 [生理学];
学科分类号
071003 ;
摘要
Nonalcoholic fatty liver disease (NAFLD) is characterized by hepatic lipid deposition and coincides often with cardiometabolic diseases. Several dietary factors attenuate NAFLD. Here, we report beneficial effects of chronic dietary capsaicin intake on NAFLD which is mediated by the transient receptor potential vanilloid 1 (TRPV1) activation. The results showed that TRPV1 activation by capsaicin reduced free fatty acids (FFAs) induced the intracellular lipid droplets in HepG2 cells and prevented fatty liver in vivo. Chronic dietary capsaicin promoted lipolysis by increasing hepatic phosphorylated hormone-sensitive lipase (phospho-HSL), carnitine palmitoyltransferase 1 (CPT1), and peroxisome proliferator-activated receptor delta (PPAR delta) in wild-type (WT) mice. This effect was absent in TRPV1(-/-) mice. Dietary capsaicin did not affect lipogenesis, as indicated by the detection of hepatic fatty acid synthase (FAS), sterol regulatory element-binding protein-1 (SREBP-1), PPAR alpha, and liver X receptor (LXR) in mice. Importantly, TRPV1 causes PPAR delta activation which significantly increased the expression of autophagy-related proteins, such as light chain 3 (LC3)II, Beclin1, Atg5, and Atg7 in HepG2 cells. In the in vivo study, TRPV1 activation by dietary capsaicin enhanced hepatic PPAR delta and autophagy-related proteins and reduced hepatic enzymes and inflammatory factor in WT but not TRPV1(-/-) mice. TRPV1 activation by dietary capsaicin prevents NAFLD through PPAR delta-dependent autophagy enhancement in mice. Dietary capsaicin may represent a beneficial intervention in populations at high risk for NAFLD.
引用
收藏
页码:1303 / 1316
页数:14
相关论文
共 50 条
  • [21] Peroxisome Proliferator-Activated Receptor and Retinoic X Receptor in Alcoholic Liver Disease
    Mello, Tommaso
    Polvani, Simone
    Galli, Andrea
    PPAR RESEARCH, 2009, 2009
  • [22] Oxymatrine ameliorates non-alcoholic fatty liver disease in rats through peroxisome proliferator-activated receptor-α activation
    Shi, Lijuan
    Shi, Lei
    Zhang, Hefang
    Hu, Zhijuan
    Wang, Chao
    Zhang, Donghui
    Song, Guangyao
    MOLECULAR MEDICINE REPORTS, 2013, 8 (02) : 439 - 445
  • [23] Epigenetic Regulation of Insulin Resistance in Nonalcoholic Fatty Liver Disease: Impact of Liver Methylation of the Peroxisome Proliferator-Activated Receptor γ Coactivator 1α Promoter
    Sookoian, Silvia
    Soledad Rosselli, Maria
    Gemma, Carolina
    Burgueno, Adriana L.
    Fernandez Gianotti, Tomas
    Castano, Gustavo O.
    Pirola, Carlos J.
    HEPATOLOGY, 2010, 52 (06) : 1992 - 2000
  • [24] Telmisartan downregulates angiotensin II type 1 receptor through activation of peroxisome proliferator-activated receptor γ
    Imayama, Ikuyo
    Ichiki, Toshihiro
    Inanaga, Keita
    Ohtsubo, Hideki
    Fukuyama, Kae
    Ono, Hiroki
    Hashiguchi, Yasuko
    Sunagawa, Kenji
    CARDIOVASCULAR RESEARCH, 2006, 72 (01) : 184 - 190
  • [25] Pan-peroxisome proliferator-activated receptor agonist lanifibranor as a dominant candidate pharmacological therapy for nonalcoholic fatty liver disease
    Yoneda, Masato
    Kobayashi, Takashi
    Asako, Nogami
    Iwaki, Michihiro
    Saito, Satoru
    Nakajima, Atsushi
    HEPATOBILIARY SURGERY AND NUTRITION, 2022, 11 (03) : 433 - 435
  • [26] Effects of peroxisome proliferator-activated receptor agonists on murine nonalcoholic liver injury.
    Fujii, K
    Nishitani, Y
    Matsumoto, H
    ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH, 2004, 28 (08) : 10A - 10A
  • [27] Role of hepatic peroxisome proliferator-activated receptor γ in non-alcoholic fatty liver disease
    Lee, Samuel M.
    Muratalla, Jose
    Sierra-Cruz, Marta
    Cordoba-Chacon, Jose
    JOURNAL OF ENDOCRINOLOGY, 2023, 257 (01)
  • [28] Peroxisome Proliferator-Activated Receptor-δ as Emerging Target in Liver Disease
    Schnabl, Bernd
    DRUG DEVELOPMENT RESEARCH, 2010, 71 (02) : 106 - 111
  • [29] The role of peroxisome proliferator-activated receptor in the treatment of non-alcoholic fatty liver disease
    Sun, Xin
    Zhang, Yan
    Xie, Meilin
    ACTA PHARMACEUTICA, 2017, 67 (01) : 1 - 13
  • [30] A common variant in the peroxisome proliferator-activated receptor-γ coactivator-1α gene is associated with nonalcoholic fatty liver disease in obese children
    Lin, Yu-Cheng
    Chang, Pi-Feng
    Chang, Mei-Hwei
    Ni, Yen-Hsuan
    AMERICAN JOURNAL OF CLINICAL NUTRITION, 2013, 97 (02): : 326 - 331